N4 Pharma (LON:N4P) Shares Up 11.1% – What’s Next?

N4 Pharma Plc (LON:N4P) shares rose 11.1% during mid-day trading on Monday . The company traded as high as GBX 0.50 ($0.01) and last traded at GBX 0.50 ($0.01). Approximately 5,043,673 shares were traded during trading, an increase of 165% from the average daily volume of 1,901,099 shares. The stock had previously closed at GBX 0.45 ($0.01).

N4 Pharma Stock Performance

The stock has a market cap of £4.16 million, a P/E ratio of -161.29 and a beta of -0.37. The stock has a 50-day moving average price of GBX 0.43 and a 200-day moving average price of GBX 0.46.

N4 Pharma (LON:N4P) last issued its quarterly earnings results on Monday, June 9th. The company reported GBX (0.31) earnings per share (EPS) for the quarter. N4 Pharma had a negative net margin of 18,399.86% and a negative return on equity of 90.68%.

About N4 Pharma

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma’s lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.